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Controlled delivery of SDF-1α and IGF-1: CXCR4+
cell recruitment and functional skeletal muscle
recovery
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Melissa Merscham-Banda,a Laura J. Suggsb and Roger P. Farrar*a
Therapeutic delivery of regeneration-promoting biological factors directly to the site of injury has demon-
strated its eﬃcacy in various injury models. Several reports describe improved tissue regeneration follow-
ing local injection of tissue speciﬁc growth factors, cytokines and chemokines. Evidence exists that
combined cytokine/growth factor treatment is superior for optimizing tissue repair by targeting diﬀerent
aspects of the regeneration response. The purpose of this study was to evaluate the therapeutic potential
of the controlled delivery of stromal cell-derived factor-1alpha (SDF-1α) alone or in combination with
insulin-like growth factor-I (SDF-1α/IGF-I) for the treatment of tourniquet-induced ischemia/reperfusion
injury (TK-I/R) of skeletal muscle. We hypothesized that SDF-1α will promote sustained stem cell recruit-
ment to the site of muscle injury, while IGF-I will induce progenitor cell diﬀerentiation to eﬀectively
restore muscle contractile function after TK-I/R injury while concurrently reducing apoptosis. Utilizing a
novel poly-ethylene glycol PEGylated ﬁbrin gel matrix (PEG-Fib), we incorporated SDF-1α alone (PEG-Fib/
SDF-1α) or in combination with IGF-I (PEG-Fib/SDF-1α/IGF-I) for controlled release at the site of acute
muscle injury. Despite enhanced cell recruitment and revascularization of the regenerating muscle after
SDF-1α treatment, functional analysis showed no beneﬁt from PEG-Fib/SDF-1α therapy, while dual deliv-
ery of PEG-Fib/SDF-1α/IGF-I resulted in IGF-I-mediated improvement of maximal force recovery and
SDF-1α-driven in vivo neovasculogenesis. Histological data supported functional data, as well as high-
lighted the important diﬀerences in the regeneration process among treatment groups. This study pro-
vides evidence that while revascularization may be necessary for maximizing muscle force recovery,
without modulation of other eﬀects of inﬂammation it is insuﬃcient.
Introduction
Skeletal muscle tissue has a remarkable ability to regenerate.
Nevertheless, muscle regenerative capacity is reduced during
ageing and can be greatly compromised following severe inju-
ries.1 Functional deficits are commonly a consequence of
impaired regenerative responses, leading to partial or complete
loss of muscle function.2
In animal models cell-based therapies have been used suc-
cessfully to enhance muscle regeneration.3–9 Transfers of myo-
blasts/satellite cells,10 mesenchymal cells,11 bone marrow-
derived stem cells,12,13 peripheral blood-derived stem cells14
and other tissue resident stem cell populations3,8 with multi-
lineage potential are tested with hopes to develop viable treat-
ments for skeletal muscle injuries and muscle wasting dis-
orders. In pre-clinical trials myoblast transplantation showed
great promise for the treatment of localized muscular dystro-
phies as well as several conditions such as urinary and anal
incontinence.7 Several serious challenges still preclude the
widespread use of stem-cell based therapies in clinic: (1) the
need for standardized in vitro culture systems to raise
suﬃcient and homogeneous stem cell populations;6,15 and (2)
the ability to control cell fate before and after transplantation
to avoid undesirable transdiﬀerentiation and potential for
malignant transformation.16 Although, such issues as immune
rejection, poor survival, limited traﬃcking and engraftment at
the site of injury are existing limitations,7 several studies still
show transient benefits from stem cell therapies due to the
modulation of local inflammation through the release of anti-
inflammatory mediators, as well as secondary eﬀects on resi-
dent or locally recruited cells.12,13,17–21 Overall, with better
characterization of microenvironmental components influen-
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cing the outcome of tissue regeneration, more combination
therapies are likely to emerge including simultaneous delivery
of several growth factors, cytokines and chemokines, co-trans-
plantation of multiple cell populations and combinatorial
treatments with both growth factors/cytokines/chemokines
and cells. As such, co-transplantation studies using innate
immune cells and human myoblasts were eﬀective at stimulat-
ing myoblast proliferation and engraftment into mouse dys-
trophic muscle.22 Co-delivery of SDF-1α transgene and
endothelial progenitors enhanced cell engraftment and sub-
sequent angiogenesis of the ischemic muscle.23 Despite recent
developments, the use of stem cell therapies is precluded by
safety concerns. Therefore, identification of stem cell-trophic
and regulatory factors and their subsequent incorporation into
biodegradable matrices for the delivery into injured tissues
represents a safer alternative to cell-based therapies.
Various synthetic scaﬀolds have been designed to deliver
biomolecules to the site of acute injury.24–26 Polyethylene
glycol (PEG) is a synthetic polymer. It has been used extensively
for delivering covalently attached proteins in vivo. PEG-fibrino-
gen (PEG-Fib) results from coupling of PEG with fibrinogen
molecules, enabling generation of a biodegradable PEG-Fib
matrix after thrombin addition, while maintaining the capacity
to covalently bind various protein factors. This biological
scaﬀold is useful in several aspects: (1) it provides controlled
release of conjugated protein factors; (2) it decreases the rate of
protein clearance by the immune system; and (3) it localizes the
delivery of protein factors to a particular site or tissue.27
Recently our group used PEG-Fib to conjugate and deliver IGF-I
to improve functional recovery of skeletal muscle following
TK-I/R injury.28 Zhang et al.29 successfully used PEG-Fib matrix-
based delivery of SDF-1α to enhance myocardial remodeling.
Delivery of SDF-1α as well as other cytokines, chemokines and
growth factors directly to the site of acute injury has been suc-
cessfully accomplished by other research groups.24–26
SDF-1α or CXCL12 is a small pro-inflammatory cytokine. Its
expression is transiently induced after ischemic injury in
several tissues including skeletal muscle.30,31 During inflam-
mation and injury, SDF-1α was shown to be the most potent
chemoattractive signal for CXCR4+ cells and is considered a
major stem cell homing factor.32,33 CXCR4-expressing cells
include hematopoietic stem cells,29 endothelial progenitor
cells,23,32,34 mesenchymal stem cells,35 satellite cells36 as well
as monocytes and lymphocytes.33 In the models of ischemic
limb damage, SDF-1α was shown to restore perfusion and
enhance regeneration via recruitment of a CXCR4+ cell fraction
with pro-angiogenic properties.25,37 In contrast, in a model of
kidney I/R injury SDF-1α was shown to have no eﬀects on
recruitment of stem cells to the kidney, however, disruption of
SDF-α1 severely increased renal dysfunction and injury38,39
highlighting its requirement in locally mediated tissue repair.
Injury models of myocardial regeneration provide substantial
evidence that SDF-1α mediated therapies are beneficial due to
improved survival of local and recruited progenitor cells as
well as enhanced neovascularization.29,40 Overall, strong evi-
dence exists for the requirement of SDF-1α-mediated signaling
in orchestration of tissue regeneration, albeit the exact mecha-
nisms of action may be tissue- and injury-specific.
IGF-I is a pro-regenerative,41 anti-inflammatory growth
factor.42 Major eﬀects of IGF-I include regulation of myoblast
proliferation, diﬀerentiation and survival,41,43 modulation of
inflammatory response,42 stimulation of anabolic
pathways44–46 and atrophy prevention.47 Our group has pre-
viously shown major pro-regenerative eﬀects of IGF-I following
in vivo PEG-Fib/IGF-I delivery into the TK-I/R injured muscle.28
Motivated by our previous findings that PEG-Fib/IGF-I deliv-
ery significantly enhances muscle regeneration we wanted to
address the therapeutic eﬃcacy of combined PEG-Fib/SDF-1α/
IGF-I and PEG-Fib/SDF-1α therapies on functional muscle
regeneration following TK-I/R injury. We hypothesized that ele-
vating and maintaining SDF-1α levels via PEG-Fib-mediated
release at the site of I/R injury will promote the recruitment of
resident, as well as circulating CXCR4-expressing progenitor
cells, to the site of injury. In turn, combined incorporation of
IGF-I into a biodegradable matrix should further stimulate
stem cell proliferation and diﬀerentiation to subsequently
improve functional regeneration of TK-I/R injured muscle.
Materials and methods
Animals
Male Sprague-Dawley rats (6–9 months; Charles River) were
maintained on a 12-hour light/dark cycle and housed indivi-
dually. Animals were allowed ad libitum access to food and
water. All experimental procedures were approved and conducted
in accordance with guidelines set by the University of Texas at
Austin and the Institutional Animal Care and Use Committee.
Tourniquet application
The 2-hour tourniquet-induced ischemia/reperfusion (TK-I/R)
model of skeletal muscle injury was induced as previously
described.2 Briefly, randomly selected hind limb was elevated
and a pneumatic tourniquet cuﬀ (D.E. Hokanson, Inc.; Belle-
vue, WA) was placed proximal to the knee. The cuﬀ was
inflated to 250 mmHg using the Portable Tourniquet System
(Delfi Medical Innovations Inc.; Vancouver, BC, Canada) for
2 hours. During the course of this procedure, rats were
anesthetized with 2% to 2.5% isoflurane and body heat was
maintained with the use of a heat lamp. The analgesic, carpro-
fen, was administered prior to tourniquet application, 12- and
24-hours post-TK-I/R injury for pain management.
PEGylated fibrin preparation and delivery
Protein factor conjugated PEGylated fibrin gel was prepared as
previously described.27,29 Briefly, human fibrinogen (Sigma-
Aldrich Co.; St. Louis, MO) was reconstituted in Tris-buﬀered
saline (40 mg mL−1, pH 7.8) and reacted with bifunctional
SG-PEG-SG (NOF America Corp, Irvine, CA) in 5 : 1 PEG :
fibrinogen molar ratio with or without the addition of rat
SDF-1α (PeproTech Inc.; Rocky Hill, NJ) and human IGF-I
(Pepro Tech Inc.; Rocky Hill, NJ). Gel polymerization was
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induced by the addition of 25 U mL−1 of human thrombin
(Sigma). The final concentration of fibrinogen was 10 mg
mL−1, PEG 0.5 mg ml−1, SDF-1α 10 μg mL−1, IGF-I 25 μg ml−1.
Twenty-four hours post TK-I/R injury, 0.25 mL of empty
PEGylated fibrin gel (Peg-Fib; n = 6), SDF-1α conjugated
PEGylated fibrin gel (Peg-Fib/SDF-1α; n = 6), SDF-1α and IGF-I
conjugated PEGylated fibrin gel (Peg-Fib/SDF-1α/IGF-1; n = 6)
was injected into the lateral gastrocnemius (LGAS) muscle of
the TK-injured limb. PEG-Fib-containing treatments were
injected in liquid form and polymerized in situ. Functional
assessments were performed at 14 days of reperfusion.
Functional assessment
Following 14 days of TK-I/R injury, in situ evaluations of lateral
gastrocnemius (LGAS) force production were performed on the
tourniquet and contralateral leg (uninjured) as previously
described.2 Briefly, animals were anesthetized with isoflurane,
and the skin of the hindlimb was removed to expose the ham-
string. LGAS muscle was isolated; innervation to the medial
GAS was removed. The Achilles tendon was attached to the
lever arm of a dual mode servomotor (Aurora Scientific Model
310B Inc.; Aurora, ON, Canada). The muscle was stimulated
using a stimulator (A-M Systems, Carlsborg, WA, Model 2100)
with electrodes applied to the tibial nerve. Optimal length (Lo)
was determined by finding the length producing the maximal
twitch force at 0.5 Hz at 5 V. Maximal peak tetanic tension (Po)
was measured at 150 Hz and the minimal voltage required to
elicit a maximal Po response. Each tetanic contraction was fol-
lowed by 2 minutes of rest. Muscle temperature was main-
tained with a heat lamp and warm mineral oil. Data was
collected and analyzed using LabView software. After the com-
pletion of the contractile measurements, the muscles were har-
vested, weighed, embedded in OCT compound, and frozen in
liquid nitrogen-cooled isopentane. The muscles were stored in
a −80 °C freezer until histological analysis.
Histological analysis, immunofluorescent and
immunohistochemical tissue staining
Frozen, OCT-embedded muscle samples following 14 days of
recovery after I/R injury were sectioned on a cryostat (Leica
CM1900; Leica Microsystems Inc.; Buﬀalo Grove, IL) and
placed on a warm slide. Hematoxylin & eosin (H&E) s and
Masson’s trichrome (Polyscience, Warrington, PA, USA) stain-
ing were performed as previously described,28 and slides were
observed with a light microscope (Nikon Diaphot, Nikon
Corp.; Tokyo, Japan) with the 20× objective lens. Images were
taken using a mounted digital camera (Optronix Microfire;
Optronix; Goleta, CA). Myofiber cross-sectional area (CSA) was
measured using ImageJ software. Immunofluorescence proto-
cols were previously described.48 Briefly, sectioned tissue was
blocked with 5% normal donkey serum and 1% BSA in PBS,
and stained with primary anti-CXCR4 antibody (1 : 200; Novus
Biologicals, Littleton, CO, USA, H00007852-M04). Primary anti-
body staining was detected with the donkey anti-mouse
IgG-TRITC fluorescein (1 : 100; Santa Cruz Biotechnology, Inc.;
Santa Cruz, CA) and counterstained with DAPI (1 : 1000; Mole-
cular Probe, OR, USA, D1306). CXCR4+ cells were identified
using Leica (DM IL) fluorescence microscope with the 20×
objective lens, photographed using AxioCam MRm Microscope
Camera and quantified using ImageJ Software. PEG-Fib group
n = 6; PEG-Fib/SDF-1 group n = 5 control leg, n = 6 TK leg;
PEG-Fib/SDF-1/IGF-I group n = 5.
To measure CD31+ cell density, sections were stained sec-
tions with the anti-rat CD31 (PECAM-1) antibody (1 : 25; BD
Pharmingen, San Jose, CA, USA, 550300) followed by incu-
bation with the avidin-biotin enzyme kit (Vectastain ABC Kit;
Vector Laboratories, Irvine, CA, USA) and Pierce DAB substrate
kit (Thermo Scientific, Rockford, IL, USA). CD31+ cell density
was determined from the number of CD31+ cell per muscle
fiber using Image J software.
Western blotting
Western blotting was performed as previously described.49
Briefly, samples were prepared and boiled in 2× Laemmli’s
sample buﬀer at a ratio of 1 : 1 for 5 minutes, samples were
loaded into each well of a 5% stacking/12.5% separating poly-
acrylamide gel. Following SDS-PAGE, proteins were transferred
to a PVDF membrane (Millipore) and blocked with 5% milk in
0.1% Tween-20 in TBS (TBST) for 1 h. Membrane was incu-
bated in a 1 : 1000 dilution of primary antibody to rabbit anti-
rat SDF-1α (Peprotech) in 5% milk-TBST overnight at 4 °C.
Protein bands were detected using 1 : 1000 dilution of goat
anti-rabbit horseradish peroxidase-conjugated secondary anti-
body (Pierce) in 5% milk-TBST for 2 h. Following detection of
SDF-1α protein, membrane was washed, incubated in stripping
buﬀer at 50 °C for 50 min, blocked and re-blotted with
primary rabbit anti-human IGF-I antibody (Peprotech) at
1 : 1000 dilution overnight at 4 °C. Secondary detection was
performed as described above. Blots were imaged with the
Chemidoc XRS system (Bio-Rad).
Statistical analysis
Functional values were analyzed using one-way ANOVA to
compare groups, and the Tukey post-hoc test was used to
compare between data sets (p < 0.05). The values are rep-
resented as the mean ± SEM, unless noted otherwise.
Results
Identification of SDF-1α and IGF-I by western blot
Our group has previously shown the successful conjugation of
IGF-I growth factor to PEG-Fib matrix.28 In turn, the success of
SDF-1α conjugation to PEG-Fib matrix was extensively charac-
terized by Zhang et al.29 We utilized already established proto-
cols to conjugate SDF-1α and IGF-I to the PEGylated fibrin
matrix. By using Western Blot we confirmed the presence of
SDF-1α and IGF-I in our gels (Fig. 1). Co-incubation of SDF-1α
and IGF-I recombinant proteins with PEG-Fib matrix resulted
in the formation of large PEG-Fib/SDF-1α/IGF-I complexes
detected by SDF-1α and IGF-I specific antibodies (Fig. 1; Lane
4). Fibrinogen (α-chain 63.5 kDa, β-chain 56 kDa, γ-chain
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47 kDa) binds PEG (3.4 kDa), SDF-1α (10 kDa) and IGF-I
(7.5 kDa) to form SDF-1α/IGF-I-containing aggregates visual-
ized at ≥60 kDa size. No staining was detected with fibrinogen
only (Lane 2) and PEGylated fibrinogen (Lane 3). Success of
the PEGylation procedure is reflected in the virtual absence of
staining to unconjugated SDF-1α and IGF-I (Fig. 1; Lane 4).
Our prior work has demonstrated progressive release of
SDF-1α and IGF-I from PEG-Fib matrix in vitro.28,29
SDF-1α delivery promotes the persistence of CXCR4+ cells at
the site of injury 14 days post-reperfusion
The aim of this experiment was to address whether PEG-Fib/
SDF-1α delivery was eﬀective in promoting the recruitment
CXCR4+ cells to the site of injury. In vitro release kinetics
showed that SDF-1α can be progressively released across
7 days.29 We hypothesized that progressive release of high con-
centrations of SDF-1α from PEG-Fib matrix in the presence of
the inflammatory response will eﬃciently recruit high
numbers of CXCR4+ cells to the site of I/R injury. To address
this, we used fluorescence microscopy to identify CXCR4-
expressing cells within TK-I/R injured skeletal muscle treated
with PEG-Fib, PEG-Fib/SDF-1α, PEG-Fib/IGF-I and PEG-Fib/
SDF-Iα/IGF-I at a late time point of 14 days post-reperfusion.
As expected, we saw significantly higher CXCR4+ cells present
within injured muscles treated with PEG-Fib/SDF-1α (19.12 ±
6.39% vs. 4.64 ± 1.52%) compared to other groups (Fig. 2).
Interestingly, the presence of IGF-I was enough to suppress the
eﬀects of SDF-1α on the recruitment of CXCR4+ cells (Fig. 2).
SDF-1α treatment of injured skeletal muscle enhances tissue
revascularization
CXCR4 receptor is highly expressed on endothelial cells as well
as endothelial cell progenitors rendering these cells sensitive
to chemotactic gradients of SDF-1α.50–52 In vitro and in vivo
models show strong eﬀects from the SDF-1/CXCR-4 axis on
tissue neoangiogenesis and neovascularization.50 We
addressed whether PEG-Fib/SDF-1α treatment alone or in com-
bination with IGF-I had an eﬀect on muscle revascularization
after I/R injury. Both treatment groups showed significantly
higher number of CD31+ cells per muscle fiber (CD31+ cells/
Fiber) when compared to uninjured control, PEG-Fib and
PEG-Fib/IGF-I groups (Fig. 3). These findings support literature
reported pro-angiogenic eﬀects of SDF-1α as well as provide
additional evidence for significant increases in revasculariza-
Fig. 1 Western blots showing the binding of SDF-1α and IGF-I to conju-
gated poly(ethylene glycol) (PEG) ﬁbrinogen (Fib). Lane 1: recombinant
rat SDF-1α (20 μg ml−1) (top), recombinant human IGF-I (50 μg ml−1)
(bottom); Lane 2: ﬁbrinogen (10 mg ml−1); Lane 3: PEGylated ﬁbrinogen;
Lane 4: PEGylated ﬁbrinogen/SDF-1α/IGF-I probed against SDF-1α (top)
and IGF-I (bottom) ≥60 kDa in size. Final concentrations of SDF-1α and
IGF-I following PEGylation were 10 μg ml−1 and 25 μg ml−1 respectively.
Fig. 2 Quantiﬁcation of CXCR4+ cells within I/R injured skeletal muscle
14 days post-reperfusion. Animals were treated with PEGylated ﬁbrin
(PEG-Fib), PEGylated ﬁbrin conjugated to SDF-1α (PEG-Fib/SDF-1α),
PEGylated ﬁbrin conjugated to IGF-I (PEG-Fib/IGF-1), and PEGylated
ﬁbrin conjugated to SDF-1α and IGF-I (PEG-Fib/SDF-1α/IGF-I) 24 h after
TK-I/R injury and analyzed 14 days post-reperfusion. Contralateral
control (n = 5, 3 ﬁelds of view per animal); TK-I/R (n = 6, 3 ﬁelds of view
per animal). Values expressed as mean ± SEM, one-way ANOVA, Tukey
post-hoc: *p < 0.05 versus PEG-Fib, #p < 0.05 PEG-Fib/SDF-1α versus
PEG-Fib/SDF-1α/IGF-I.
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tion of injured skeletal muscle tissue after PEG-Fib-mediated
SDF-1α delivery.
Improved functional regeneration after PEGylated fibrin
delivery of IGF-I without therapeutically beneficial eﬀects from
SDF-1α
We aimed to determine the eﬃcacy of PEG-Fib-mediated con-
trolled release of SDF-1α and IGF-I directly at the site of I/R
injury on functional recovery of skeletal muscle. To address
this, we administered either empty PEG-Fib matrix, PEG-Fib
matrix conjugated to SDF-1α or PEG-Fib matrix conjugated to
SDF-1α/IGF-I i.m. into TK-I/R injured LGAS 24 h after TK
release. Surprisingly, we observed no significant diﬀerence in
maximum force production recovery with PEG-Fib/SDF-1α
(52.05 ± 6.00%) compared to the PEG-Fib (49.48 ± 9.87%) treat-
ment groups. As expected, PEG-Fib/SDF-1α/IGF-1 treatment
resulted in improved recovery of force, compared to PEG-Fib
treatment (66.50 ± 13.37% vs. 49.48 ± 9.87%; P < 0.05) as seen
in Fig. 4. The tetanic force production in PEG-Fib/SDF-1α/IGF-I
group was similar to maximum force production achieved fol-
lowing PEG-Fib/IGF-I treatment28 suggesting that positive
eﬀect from treatment was primarily due to the presence and
bioactivity of IGF-I.
Specific tension values (SP0) were determined across groups
in order to normalize tetanic forces to muscle cross sectional
areas. Consistent with force recovery values, there were no sig-
nificant diﬀerences between specific tensions for the PEG-Fib
(10.59 ± 2.41 N cm−2) and PEG-Fib/SDF-1α (10.13 ± 2.21 N
cm−2) groups. There was a significant increase in specific
tension in PEG-Fib/SDF-1α/IGF-1 group (14.22 ± 1.79 N cm−2)
compared to PEG-Fib and PEG-Fib/SDF-1α groups (p < 0.05)
(Fig. 5). Previous delivery PEG-Fib and PEG-Fib/IGF-I into TK-I/
R injured muscle generated SP0 values of 11.7 ± 1.0 N cm
−2
and 14.8 ± 0.6 N cm−2 respectively28 supporting consistency of
Fig. 4 Percent maximum force production recovery among treatment
groups 14 days after I/R injury. Maximum tetanic force production (P0)
of the LGAS was measured in situ from the following groups: PEGylated
ﬁbrin (PEG-Fib), PEGylated ﬁbrin conjugated to SDF-1α (PEG-Fib/SDF-1),
and PEGylated ﬁbrin conjugated to SDF-1α and IGF-I (PEG-Fib/SDF-1α/
IGF-I). The P0 were compared to the contralateral leg that received no
injury. Values expressed as mean ± SEM, one-way ANOVA, Tukey post-
hoc: *p < 0.05 versus PEG-Fib, n = 6.
Fig. 3 Identiﬁcation and quantiﬁcation of CD31+ cells within I/R injured skeletal muscle 14 days post-reperfusion. Animals were treated with PEGy-
lated ﬁbrin (PEG-Fib), PEGylated ﬁbrin conjugated to SDF-1α (PEG-Fib/SDF-1α), PEGylated ﬁbrin conjugated to IGF-I (PEG-Fib/IGF-1), and PEGylated
ﬁbrin conjugated to SDF-1α and IGF-I (PEG-Fib/SDF-1α/IGF-I) 24 h after TK-I/R injury and analyzed 14 days post-reperfusion. Representative images
of CD31+ staining (200×) and quantiﬁcation of CD31+ cells/muscle ﬁber (n = 3, 3 ﬁelds of view per animal). Values expressed as mean ± SEM, one-
way ANOVA, Tukey post-hoc: *p < 0.05 versus uninjured control, #p < 0.05 versus PEG-Fib group, †p < 0.05 versus PEG-Fib/SDF-1α group.
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our data and highlighting the lack of SDF-1α eﬀect in the
PEG-Fib/SDF-1α/IGF-1 group. Muscle weights across groups
were not significantly diﬀerent (data not shown).
These results suggest that SDF-1α delivery to TK-I/R injured
muscle does not provide significant therapeutic benefit. The
beneficial eﬀect from dual PEG-Fib/SDF1α/IGF-I factor delivery
is mediated primarily by IGF-I.
Histological evaluation of regenerating muscle tissue supports
functional results, but points to diﬀerences in regeneration
mechanisms among groups
Histological evaluation of H&E stained muscle sections at
14 days post-reperfusion in general supports the functional
data results described above, albeit, several important and
interesting distinctions are apparent between groups. For
example, the PEG-Fib/SDF-1α treatment group showed a much
greater distribution of smaller myofibers than the PEG-Fib
group despite similar contractile deficiencies (Fig. 6A and B).
This may point to potential diﬀerences in the regeneration
process that may have taken place subsequent to SDF-1α deliv-
ery. The presence of large myofibers of round morphology in
PEG-Fib samples is most likely an indication of an ongoing
regeneration process. Also, inflammatory exudate and fibrotic
areas are evident during gross examination of muscle sections
treated with PEG-Fib (Fig. 6A). Persistent inflammation within
regenerating tissue has been associated with increased col-
lagen deposition.53 In turn, increased fibrosis may lead to con-
tractile dysfunction by decreasing myofiber occupancy. We
evaluated collagen deposition in our tissues using Trichrome
staining. As expected, we saw significantly higher fibrosis in
PEG-Fib and PEG-Fib/SDF-1α treated muscles (Fig. 7).
Muscles treated with PEG-Fib/SDF-1α/IGF-I, as expected,
showed almost no signs of injury induced pathology and
minimal fibrosis, their myofiber size distribution was compar-
able to that of control muscle (Fig. 6C and 7). Histologically
(H&E), muscles treated with PEG-Fib/SDF-1α/IGF-I look identi-
cal to muscle treated with PEG-Fib/IGF-I.28 Therefore, histo-
logical examination supports functional studies and provides
further evidence that SDF-1α delivery via PEG-Fib does not
enhance myofiber regeneration despite enhanced revasculari-
zation at 14 days after I/R injury. We believe that the beneficial
eﬀect from dual PEG-Fib/SDF-1α/IGF-I delivery is mainly due
to the eﬀect of IGF-I on muscle force recovery. Whether the
lack of beneficial eﬀects at 14 days in PEG-Fib/SDF-1α group
indicates delayed resolution of inflammation during the acute
stages of muscle regeneration was not determined.
In conclusion, we have shown that PEG-Fib mediated deliv-
ery of the chemokine, SDF-1α recruits CXCR4+ cells to the
injured muscle, enhances muscle neovascularization, however,
does not accelerate force recovery and myofiber regeneration
in I/R injured skeletal muscle at 14 days. In contrast, dual
PEG-Fib-mediated delivery of SDF-1α/IGF-I improves tissue
revascularization, leads to increased myofiber size and
decreased muscle tissue fibrosis. Most importantly, dual
SDF-1α/IGF-I treatment enhances functional regeneration of
skeletal muscle tissue after TK-I/R injury, although, positive
eﬀects on skeletal muscle force recovery appear to be primarily
IGF-I-mediated.
Discussion
In this study we used a PEGylated fibrin-based matrix to
deliver SDF-1α chemokine alone or in combination with IGF-I
growth factor to the site of acute skeletal muscle TK-I/R injury.
Motivated by our previous success in the delivery of PEG-Fib/
IGF-I to enhance functional muscle regeneration after I/R
injury28 we aimed to address the eﬃciency of a combined
matrix-based SDF-1α/IGF-I therapeutic approach on restoring
muscle function post TK-I/R injury. We found no added
benefit on the restoration of muscle contractile function from
combined PEG-Fib/SDF-1α/IGF-I therapy compared to
PEG-Fib/IGF-I treatment at the 14 day time point. However, the
presence of SDF-1α significantly enhanced muscle tissue revas-
cularization after TK-I/R injury.
Taking into consideration multiple literature-reported bene-
ficial eﬀects of SDF-1α treatment on regeneration of ischemic
tissues, including skeletal muscle,25 we were surprised to find
no functional improvements following PEG-Fib/SDF-1α
therapy. Albeit to our knowledge, we are the first group to
evaluate the eﬀect of SDF-1α treatment on functional regene-
ration of skeletal muscle after TK-I/R injury. In addition to
functional results, histological data strengthened our con-
clusions and provided additional evidence of ongoing degen-
erative/regenerative cycling at the two-week time point after
TK-I/R injury in the PEG-Fib/SDF-1α treatment group charac-
terized by an abundance of smaller myofibers and increased
Fig. 5 Functional recovery of tetanic tension among treatment groups
14 days after I/R injury. Speciﬁc tension (SP0) of the LGAS was measured
in situ for the following groups: PEGylated ﬁbrin (PEG-Fib), PEGylated
ﬁbrin conjugated to SDF-1α (PEG-Fib/SDF-1), and PEGylated ﬁbrin conju-
gated to SDF-1α and IGF-I (PEG-Fib/SDF-1/IGF-I). Values expressed as
mean ± SEM, one-way ANOVA, Tukey post-hoc: †p < 0.05 versus un-
injured, *p < 0.05 versus PEG-Fib, #p < 0.05 versus PEG-Fib/SDF-1, n = 6.
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fibrosis, despite persistence of CXCR4+ cells at the site of
injury and enhanced tissue revascularization. Although not
demonstrating a positive eﬀect at this time point, our results
were not completely unexpected.
SDF-1α is a chemokine, strongly induced in an inflamma-
tory setting.54 It is known to be a powerful chemoattractant for
CXCR4-expressing stem cell populations as well as bone
marrow-derived immune cells.33,54,55 As such, SDF-1α was
shown to be a potent chemoattractant of inflammatory mono-
cytes in vivo, greater even than action of monocyte chemo-
attractant protein-1 (MCP-1).33 Various cancers use the SDF-1α/
CXCR4 signaling axis to recruit inflammatory macrophages to
the tissues.56,57 In a model of spinal cord injury, locally
expressed SDF-1α in conjunction with matrix metalloprotei-
nase-9 supports the migration of monocytes into the injured
spinal cord.31 Another recent report provides compelling evi-
dence that the CXCR7 receptor is induced during monocyte-to-
macrophage transition and is expressed at higher levels on
M1 macrophages. Therefore, in addition to promoting macro-
phage recruitment, SDF-1α signals via CXCR7 to enhance
macrophage phagocytosis, contributing to pathogenesis of
atherosclerosis.58 Myocardial CXCR4 overexpression led to the
exacerbation of I/R injury in the heart by increasing inflamma-
tory infiltrate,59 while transendocardial delivery of SDF-1α
failed to improve myocardial perfusion and ventricular func-
tion.60 These studies suggest that exaggerated signaling via
SDF-1α-CXCR4/7 axis may lead to detrimental eﬀects on tissue
regeneration especially during early stages of muscle regene-
ration where eﬃcient resolution of the inflammatory response
is required for the timely onset of tissue repair.61,62
In our model of TK-I/R injury, tissue necrosis, vascular
damage, severe inflammation and functional deficits are the
hallmarks of I/R-induced muscle pathology.2,63 It is estab-
lished that inflammatory monocytes/macrophages (M1) are
recruited early in regeneration and, although, absolutely
required for the clearance of necrotic debris at the site of
Fig. 6 Histological analysis of I/R injured skeletal muscle 14 days post-reperfusion. H&E stained sections were examined for ﬁber size distribution
(200×). Data expressed as percent myoﬁbers of a given area (μm2). Representative images are included: (A) PEGylated ﬁbrin (PEG-Fib), (B) PEGylated
ﬁbrin conjugated to SDF-1α (PEG-Fib/SDF-1α), (C) PEGylated ﬁbrin conjugated to SDF-1α and IGF-I (PEG-Fib/SDF-1α/IGF-I).
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injury, their persistence often exacerbates inflammation and
delays regeneration.64–66 Muscle fiber necrosis following I/R
injury is a potent pro-inflammatory activator of recruited
monocytes.67 Recently, high mobility group box-1, a nuclear
protein released by necrotic cells, was shown to form a hetero-
complex with SDF-1α and act via CXCR4 to recruit inflamma-
tory cells.68 I/R-induced muscle necrosis combined with pro-
gressive release of SDF-1α from PEG-Fib matrix in our injury
model may have contributed to the recruitment of additional
inflammatory CXCR4+ cells prolonging local inflammation
and delaying onset of muscle regeneration. Immunofluores-
cence data showing increased numbers of CXCR4+ cells in
muscles treated with PEG-Fib/SDF-1α late in regeneration
response serve as evidence of either ongoing cell recruitment
or local proliferation, both of which are characteristics of early
phase regenerative events.69
In literature, the beneficial role of SDF-1α is associated with
improved restoration of ischemic tissue perfusion and neovas-
cularization.40 Several reports mention SDF-1α-recruited
CXCR4+CD11b+ cells as primary mediators of neovasculariza-
tion.37 Multiple solid tumors exploit the SDF-1α/CXCR4 axis
for the recruitment of M1 macrophages to promote and
support the establishment of the vascular supply for tumor
survival. As such, in a highly inflammatory context, a pro-
angiogenic environment leads to the formation of immature
and fragile neovessels. The recruitment of CD34+ endothelial
progenitor cells via the SDF-1α/CXCR4 signaling axis may con-
tribute to inflammatory angiogenesis.23 In our model, both
groups treated with SDF-1α showed significantly enhanced
muscle revascularization/neovascularization, even when com-
pared with uninjured control. However, administration of
PEG-Fib/SDF-1α often resulted in leakage of blood throughout
the muscle (data not shown), which can be a consequence of
rupture, permeability and lack of stability of newly formed
microvasculature in this group. The abundance of small myofi-
bers and the persistence of CXCR4+ cells at the site of injury as
late as two weeks post-reperfusion provide further evidence for
the ongoing degeneration/regeneration sequence of events.
Increased collagen deposition in PEG-Fib and PEG-Fib/SDF-1α
treated muscles may be indicative of M2 macrophage activity
in the inflammatory setting.70 These cells appear in the
muscles as early as 3 days post-reperfusion71 and produce argi-
nase-1 and TGF-β factors both of which contribute to extra-
cellular matrix deposition.72 Overall, there appears to be no
functional benefit from SDF-1α treatment up to 14 days post-
TK-I/R injury compared to matrix delivery alone, despite appar-
ent enhancement in neovascularization.
Interestingly, in the combined delivery of PEG-Fib/SDF-1α/
IGF-I, IGF-I was able to complement the SDF-1α-mediated neo-
vascularization eﬀect. Muscles treated with PEG-Fib matrix
containing both SDF-1α and IGF-I showed enhanced revascu-
larization, increased myofiber distribution, decreased fibrosis
and enhanced contractile function when compared to PEG-Fib
matrix delivery alone. Our group has previously shown signifi-
Fig. 7 Quantiﬁcation of collagen deposition in I/R injured skeletal muscle 14 days post-reperfusion. Animals were treated with PEGylated ﬁbrin
(PEG-Fib), PEGylated ﬁbrin conjugated to SDF-1α (PEG-Fib/SDF-1α), and PEGylated ﬁbrin conjugated to SDF-1α and IGF-I (PEG-Fib/SDF-1α/IGF-I)
24 h after TK-I/R injury and analyzed 14 days post-reperfusion. Representative images of trichrome staining (200×) where collagen staining is shown
in blue (n = 3, 3 ﬁelds of view per animal). Values expressed as mean ± SEM, one-way ANOVA, Tukey post-hoc: *p < 0.05 versus PEG-Fib group.
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cant beneficial eﬀects of PEG-Fib/IGF-I administration on
muscle recovery following TK-I/R injury. It was apparent that
functional improvements using PEG-Fib/SDF-1α/IGF-I therapy
were very similar to functional recovery using PEG-Fib/IGF-I
therapy of TK-I/R injured muscles.28 Therefore, we concluded
that beneficial eﬀects of PEG-Fib/SDF-1α/IGF-I therapy on
restoration of muscle contractile function are primarily attribu-
ted to IGF-I activity, a potent anti-inflammatory, pro-regenera-
tive, anti-apoptotic and hypertrophy-promoting growth
factor.42 In order to better understand the eﬀect of exogenous
SDF-1α delivery on muscle regeneration, we need to perform
additional functional testing to evaluate the benefit of
enhanced vascularization on restoration of work capacity in
PEG-Fib/SDF-1α/IGF-I treatment group, as well as characterize
and quantify SDF-1α-mediated eﬀects on inflammatory and
precursor cells recruitment at the early stages of muscle
regeneration.
The release kinetics of SDF-1α/IGF-1 from PEG-Fib matrix
were previously evaluated by our group as well as Zhang et al.29
Sequence of factor release at the site of acute injury may be
responsible for the therapeutic eﬀect seen after dual PEG-Fib/
SDF-1α/IGF-I delivery. The majority of IGF-I is released from
the matrix within the first 24 hours and at physiologically rele-
vant levels over a 4-day period, while slightly larger SDF-I is
progressively released over 7 days. The powerful anti-inflam-
matory, pro-regenerative signal delivered via IGF-I may have
inhibited SDF-1-dependent inflammatory cell recruitment at
the later stages of muscle regeneration and/or facilitated
earlier inflammatory resolution and onset of tissue repair.
Future studies should address how changing the order and
kinetics of SDF-1α/IGF-I release may impact functional tissue
regeneration.
Conclusion
We did not observe functional improvements after PEG-Fib/
SDF-1α treatment, despite treatment-induced increase in per-
sistence of CXCR4+ cells and enhanced tissue revascularization
at two weeks after initial injury. Functional analysis showed no
significant diﬀerence in maximal force recovery between
matrix alone treatment and addition of SDF-1α. As expected,
combined PEG-Fib/SDF-1α/IGF-I delivery in addition to
enhanced revascularization, significantly improved functional
recovery following TK-I/R. However, the eﬀect of combined
PEG-Fib/SDF-1α/IGF-I therapy on recovery of muscle force
appeared to be IGF-I mediated. Our data confirm the require-
ment for IGF-I in promoting muscle repair and pro-angiogenic
eﬀects of SDF-1α on tissue revascularization. We did not show
beneficial eﬀects of SDF-1α treatment on contractile force
recovery at 14 days after TK-I/R injury. Nevertheless, combined
growth factor therapy can oﬀer multiple benefits provided that
one can manipulate the release order, kinetics and gradients
of delivered mediators in the microenvironment in spatio-
temporal manner to promote eﬃcient repair.
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